0000899243-19-002189.txt : 20190130
0000899243-19-002189.hdr.sgml : 20190130
20190130160701
ACCESSION NUMBER: 0000899243-19-002189
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190111
FILED AS OF DATE: 20190130
DATE AS OF CHANGE: 20190130
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HEALY JAMES
CENTRAL INDEX KEY: 0001245624
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36721
FILM NUMBER: 19552004
MAIL ADDRESS:
STREET 1: 3000 SAND HILL ROAD, 4-250
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Coherus BioSciences, Inc.
CENTRAL INDEX KEY: 0001512762
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 273615821
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O DENNIS M. LANFEAR
STREET 2: 333 TWIN DOLPHIN DR, SUITE 600
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
BUSINESS PHONE: (650) 649-3530
MAIL ADDRESS:
STREET 1: C/O DENNIS M. LANFEAR
STREET 2: 333 TWIN DOLPHIN DR, SUITE 600
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
FORMER COMPANY:
FORMER CONFORMED NAME: BioGenerics, Inc.
DATE OF NAME CHANGE: 20110210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-01-11
0
0001512762
Coherus BioSciences, Inc.
CHRS
0001245624
HEALY JAMES
C/O COHERUS BIOSCIENCES, INC.
333 TWIN DOLPHIN DRIVE, SUITE 600
REDWOOD CITY
CA
94065
1
0
0
0
Common Stock, $0.0001 par value
92
D
Common Stock, $0.0001 par value
2868221
I
See Footnote
Stock Option (Right to Buy)
12.37
2019-01-11
4
A
0
20000
0.00
A
2029-01-11
Common Stock
20000
20000
D
The Reporting Person is one of the managing members of the general partner of Sofinnova Venture Partners VII, L.P. that directly holds the reported securities, and as such, may be deemed to share voting and investment power with respect to such securities. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his proportionate pecuniary interest in Sofinnova Ventures Partners VII, L.P.
The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 11, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
/s/ Jean-Frederic Viret, as Attorney-in-Fact for James I. Healy, M.D., Ph.D.
2018-01-30